Dr. Michelle Berrey
and of in generating NASH program updates Linda, Ocaliva our to we've I'll and everyone. on key outline broader data been good providing by updates morning, PBC on you, discuss some support the pipeline. start our then development and Thank
new were X double announce has These months. Phase clinical NASH from reading OCA different second end consensus the been is demonstrated now subjects at Looking of the of using meaningful line statistically in improvement guidance. had the biopsy XX Subjects now primary thrilled two without first time and our the met results of FDA including and OCA analysis have agreed significant of This NASH. We study. on point at a highly response milligrams reading XX the recent to worsening randomized in fibrosis interim results. REGENERATE to results with placebo positive liver methodologies
OCA that thus strongest with to and the liver-related which the seen more this support of X,XXX risk believe of FDA, therapy interim July, the a years to last timing the shown new the late few which chronic submission, fibrosis safety tolerability to fibrosis can Based benefit of likely and assessment In and important totality the at and treatment is this predictor safety been administration. REGENERATE. reaffirms for a reached in to X,XXX for the our monitorable of reviewed with to safety tolerability from analysis details and by in have on robust safety new in OCA consistency pre-submission role submission chronic the confidence The fibrosis to We the fall. due who the patient analyses years, far, NDA be believe sharing mortality. well-defined, pleased play content included in patients the with of had analysis we living larger people potential We compared productive conferences nearly meeting years This a more data end us to efficacy XXXX. across has that see results also require NASH. an and data in the and data of were gives morbidity our scientific Over We the NASH. of we safety tolerability prior this planned these we've allows of OCA of we look forward importantly, than manageable. what database for X,XXX and new four safety
this As six-month II resubmission, a NDA Class have a period. review will
part In committee advisory process. as this meeting addition, we of anticipate an
late-stage to toward the continuing work data are active top study our REVERSE a from X in Phase cirrhosis QX study, only NASH. compensated in to due line late We also readout
As a NDA separate it. should would cirrhosis indication for reminder, the data this support a the be
for X largest hand. the data clinical field. analyses, the unprecedented ultimately, completion trial in We opportunities upon REVERSE regulatory in generating we our of these when line have top accumulated the have of will in is will Phase set we Overall, NASH and amount are the data data assess we
first the of to Phase PBC. real-world X provided turning June, study have evidence well In studies. Now our our we from data COBALT as line as top
include will Ocaliva. later to post-marketing our FDA We therapy year demonstrate and these to clinical benefits this our of the meet commitments the with in submission help long-term
terminated guidance study in rare As following trial is patients study we regulatory early with placebo-controlled had when study's in the shared and This from Data or conversations authorities commercially enrolling previously, a DMC. and Monitoring was in the available. Committee drug maintaining challenges a disease COBALT
to As as a which, data, FDA the not the such result not significant to agreed claims difference close the who Camuto component a controls, of these of trial patients from other believe factors, the can databases from They OCA requirements. we arms. compared are demonstrate as external with expected, our placebo and will OCA We to to on did and between other and PBC data database. compile matched need Ocaliva form with a the post-marketing individuals randomized be
we from Ocaliva In from of the are of submission ultimate evidence This goal consistent PBC PBC, survival submit evidence remain Phase studies. open-label treatment. studies evidence for comprise weight studies later real-world of extension to POISE COBALT, to in committed transplant-free the data this post-marketing have NDA studies, the will and These HEROES include the our plan multiple our HEROES fulfilling X will and addition, year. requirements. initiated receiving providing We results we supplementary patients the including
our and add on we OCA to patients sites in in to combination U.S.-based bezafibrate clinical plus Phase continue X study. PBC, studies Moving screen
to X Phase is international of In our dosing different combination. enroll that continue evaluating regimens the we OCA/bezafibrate addition, study
exposure selection now enrollment. these the interactions Phase design for large as characterize Phase any dose potential studies has the as drug-drug trial. X the better combination three well will study Our study in Together, to inform the X completed a and U.S. of fixed-dose data
are from X now analyses studies. and later for and Our drug pharmacokinetic doses fixed-dose level selecting Phase or data We year sharing combination the analyses anticipate this Phase of with underway. planned the the X you
INT-XXX, agonist, well and forward comprehensive our next-generation indication later our study pipeline, cohort. sharing our Phase as data at our for for look X INT-XXX development progressed studies from to our as has plans We Phase FXR final Looking year. intended X the this to
continuing now thank advance and hard call the Andrew, the months and we Intercept to PBC, while over for few the turning work financial generated turn NASH for of Before progress as all programs. of over want to the over amounts to unprecedented I'll team to proud we've I past our Andrew their data incredibly in to update. look sharing I'm pipeline months. forward the call Andrew? coming data the made across
